Deficiencies in the Fanconi Anemia or the Homologous Recombination Pathway enhance the antitumor effects of the novel hypoxia-activated prodrug CP-506
Lesley Schuitmaker, Alexander Marie-Madeleine Adrianus van der Wiel, Natasja G. Lieuwes, Rianne Biemans, Nikki A.M. Mutsters, Jennifer Jung, Victoria Claudino Bastos, Èlia Prades-Sagarra, Sheng Kuang, Jeremy S. Setton, Sabine A. S. Langie, Kim Rosalie Kampen, Jan Theys, Ala Yaromina, Ludwig Jerome Dubois, Philippe Lambin
This study shows that deficiencies in Fanconi Anemia or homologous recombination pathways enhance the antitumor effects of CP-506, a hypoxia-activated prodrug, through synthetic lethality mechanisms.
Molecular Therapy Oncology · Feb 24, 2026Peer-reviewedCancer Biology